Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Eric Van Cutsem, Geoffrey Y. Ku, Yelena Y. Janjigian et al.|The Lancet Oncology|2023

Cited by 237